CJC-1295 DAC

Mechanism

GHRH receptor agonist with a DAC tail that extends albumin binding.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Pulsatile GH restoration
• Body recomposition
• Deep sleep support

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Reported adverse effects

• Water retention

  Reportedonset: First weeksreported reversible

• Prolonged GH elevation beyond physiologic pulse

  Mechanism-linkedonset: Ongoingreported reversible

Literature on file 11

• human RCT
  Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. graded on: names a randomised controlled trial — the indexed publication type — “Randomized Controlled”
• human observational
  Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. graded on: indexed as a clinical trial, design not stated — “Clinical Trial”
• animal in vivo
  Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. graded on: an animal model — “rats”
• human observational
  A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity graded on: a registered clinical study — “clinicaltrials.gov”

Not graded

7 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (2010, cited 55x)
• not graded
  Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
• not graded
  The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
• not graded
  Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.
• not graded
  Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
• not graded
  Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
• not graded
  Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Identity

Classified as

GHRH Receptor Agonismmechanism

Most records filed under the growth hormone heading act either here or at the ghrelin receptor, and knowing which one tells you what a study actually measured: the pituitary's output, not a hormone that was injected.

Growth Hormone / IGF-1 Axispathway

The lab value people actually track, IGF-1 in ng/mL, sits two steps downstream of where most of these compounds act, so a record's mechanism and its measurable marker are rarely the same thing.

Also called

• CJC-1295 DAC
• CJC-1295 (with DAC)